Efficacy and safety profile of two-dose SARS-CoV-2 vaccines in cancer patients: An observational study in China

Table 1 Demographic and baseline characteristics of the study population in the two groups

	Healthy	Cancer	P value
Number	215	132
Age			< 0.001
mean ± SD	46.2 ± 8.1	58 ± 5.4
Sex			0.12
Male	137 (63.7%)	73 (55.3%)
Female	78 (36.3%)	59 (44.7%)
History of hypertension			0.17
Yes	69 (32.1%)	52 (39.4%)
No	146 (67.9%)	80 (60.6%)
Smoking history			0.06
Yes	50 (23.3%)	43 (32.6%)
No	165 (76.7%)	89 (67.4%)
BMI	27.5 ± 1.5	26.9 ± 1.2	< 0.001
Diabetes mellitus			0.01
Yes	21 (9.8%)	25 (18.9%)
No	194 (90.2%)	107 (81.1%)
Coronary disease			0.22
Yes	15 (7.0%)	5 (3.8%)
No	200 (93.0%)	127 (96.2%)
Respiratory disease			0.19
Yes	11 (5.1%)	3 (2.3%)
No	204 (94.9%)	129 (97.7%)
Type of vaccine			0.69
Sinovac	133 (61.9%)	85 (64.4%)
Beijing biological	49 (22.8%)	25 (18.9%)
Wuhan biological	33 (15.3%)	22 (16.7%)

BMI: Body mass index.

Table 2 Adverse effect after the first and second doses of the vaccine

Characteristic	Healthy	Cancer	P value
Overall incidence	34.4% (74/215)	28.0% (37/132)	0.215
Tired	8.8% (19)	15.9% (21)	0.045
Headache	12.1% (26)	12.9% (17)	0.829
Local pain	17.2% (37)	9.1% (12)	0.035
Fever	10.7% (23)	7.6% (10)	0.336
Erythema	8.4% (18)	6.8% (9)	0.600
Myalgia	7.0% (15)	6.1% (8)	0.739
Diarrhea	5.1% (11)	5.3% (7)	0.939
Nausea	7.4% (16)	3.8% (5)	0.166
Chills	3.7% (8)	3.8% (5)	0.975

Table 3 Vaccine features and antibody levels of the study population

Characteristic	Healthy	Cancer	P value
Antibody level (mean ± SD)	31.6 ± 4.8	25.8 ± 3.2	< 0.001
Seropositivity			< 0.001
Positive (≥ 10 AU/mL)	96.3% (207/215)	83.3% (110/132)
Negative (< 10 AU/mL)	3.7% (8/215)	16.7% (22/132)
Type of vaccine			0.206
Sinovac	97.0% (159/164)	83.2% (89/107)
Beijing biological	95.5% (42/44)	78.9% (15/19)
Wuhan biological	85.7% (6/7)	85.7% (6/7)

Table 4 Seropositivity rates of cancer patients after severe acute respiratory syndrome coronavirus 2 vaccination according to treatment status

Characteristic	Seropositivity
No therapy	94.1% (43/51)
Targeted therapy	83.3% (30/36)
Immunotherapy	74.1% (20/27)
Chemotherapy	66.7% (12/18)